A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable and Not Eligible for Local Ablation and/or TACE.

Trial Profile

A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable and Not Eligible for Local Ablation and/or TACE.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2015

At a glance

  • Drugs Sorafenib (Primary) ; Tegafur/uracil (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms SADAT
  • Most Recent Events

    • 04 Aug 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 30 Mar 2012 Trial acronym (SADAT) identified as reported by ClinicalTrials.gov.
    • 30 Mar 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top